ArticleData in brief2025
Curated and harmonised transcriptomics datasets of interstitial lung diseases.
Article in Data in brief, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Integrated Approaches in Drug Repositioning Highlight Ouabain and Helenalin as Potential Drug Candidates for Pulmonary Fibrosis.Computational and structural biotechnology journal · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study provides manually curated and homogenised transcriptomics data of interstitial lung disease (ILD) patients retrieved from the NCBI Gene Expression Omnibus and European Nucleotide Archive repositories. The compendium includes 30 transcriptomics datasets generated with DNA microarrays and RNA sequencing (RNA-seq) technologies for a total of 1371 samples. All the datasets underwent metadata curation and harmonisation, data quality check, and preprocessing with standardised procedures. Furthermore, a robust data model was developed to standardise phenotypic data, thereby enhancing comparability across heterogeneous datasets. Gene expression data and lists of differentially expressed genes computed between ILD and healthy samples are provided. Among the ILDs included in this study, idiopathic pulmonary fibrosis (IPF) is the most represented worldwide. Co-expression networks of IPF and healthy samples were inferred, which are also included in this study. This study enhances the Findability, Accessibility, Interoperability, and Reusability (FAIR) of publicly available transcriptomic datasets related to ILDs. The resulting resource provides a integrated platform for the implementation and validation of systems biology and pharmacology approaches, facilitating the development of novel diagnostic and therapeutic strategies for ILDs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.